- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07715656
Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas ((COAST))
Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas: A Randomized Controlled Trial.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sandy L Alvarez, MD
- Numéro de téléphone: 7865800186
- E-mail: sandy.l.alvarez@lahey.org
Lieux d'étude
-
-
Massachusetts
-
Burlington, Massachusetts, États-Unis, 01803
- Recrutement
- Lahey Hospital & Medical Center
-
Contact:
- Kimberly Silverman
- Numéro de téléphone: 7817443330
- E-mail: Kimberly.Silverman@lahey.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Candidates for this study must meet ALL of the following criteria:
- Subject is 18 years of age or older.
- Subject has a diagnosis of chronic subdural hematoma with mass effect Determined by brain imaging (CT or MRI) and correlated clinical symptoms.
Pre-randomization modified Rankin Score (mRS) ≤3
a. Surgical Cohort: Assessment should reflect the subject's condition just prior to undergoing surgery. Assessment may be performed post-surgery using pre-surgical data.
Subdural Hematoma Size
Medical Management Cohort:
- Midline shift < 10mm and hematoma thickness > 10 mm as measured on coronal imaging perpendicular to the skull.
- No focal deficit related to the chronic subdural hematoma requiring surgical intervention
Surgical Cohort:
• No requirement
- A CT performed prior to randomization demonstrating stability of the hematoma. Stability is defined as no worsening of midline shift or increase in the size of the cSDH from the screening image that results in new or worsening clinical symptoms.
- Patient or designated Legal Authorized Representative, confirms the patient has the mental capacity, willingness and ability to comply with protocol and follow-up requirements
- In the opinion of the treating physician, MMA embolization is technically feasible, including evaluation of preoperative CTA, if available, or presence of a foramen spinosum bilaterally.
Exclusion Criteria:
Candidates will be excluded from participation if ANY of the following apply:
- Patients presenting with an acute SDH (e.g. patient with presenting with a SDH due to trauma); mixed density is permitted.
- Subject presents with bilateral cSDHs requiring treatment (contralateral cSDH <5mm and not requiring treatment is permitted.
- Subject presents with Glasgow Coma Scale < 9
- Markwalder assessment >4
- cSDH that developed with underlying conditions such as vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, end stage renal disease (ESRD) on hemodialysis, end stage liver disease or other comorbidities causing a coagulopathy
- Prior carotid stent placement that crosses the origin of the External Carotid Artery (ECA) ipsilateral to the subdural hematoma
- Presumed septic embolus, or suspicion of microbial superinfection
- CT or MRI evidence of intra-cranial tumor or mass lesion
- Significant contraindication to angiography (eg. kidney failure).
- Life expectancy of less than 1-year
- Women who are pregnant, lactating, plan on becoming pregnant during the course of the clinical investigation. We routinely do pregnancy tests prior to this procedure, to avoid radiation exposure to the fetus including radiation on follow up CT scans
- Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Subjects in observational, natural history, and/or epidemiological studies not involving intervention are eligible
- Patient unwilling to follow SOC recommendations (e.g. refuses surgery or lifestyle modifications)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Medical Management
In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils as part of their medical management for chronic subdural hematoma (cSDH).
In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.
|
In the bilateral approach, both middle meningeal arteries are accessed and embolized using coils, regardless of hematoma location.
Imaging guidance is used throughout the procedure to ensure proper coil placement, and post-procedure imaging confirms that both vessels are fully occluded.
In the unilateral approach, the middle meningeal artery (MMA) on the side of the hematoma is accessed via a catheter and occluded using coils under imaging guidance.
The procedure targets only the affected side, and follow-up imaging is used to confirm successful embolization and vessel occlusion.
|
|
Comparateur actif: Surgical
In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils in addition to standard surgical management for chronic subdural hematoma (cSDH).
In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.
|
In the bilateral approach, both middle meningeal arteries are accessed and embolized using coils, regardless of hematoma location.
Imaging guidance is used throughout the procedure to ensure proper coil placement, and post-procedure imaging confirms that both vessels are fully occluded.
In the unilateral approach, the middle meningeal artery (MMA) on the side of the hematoma is accessed via a catheter and occluded using coils under imaging guidance.
The procedure targets only the affected side, and follow-up imaging is used to confirm successful embolization and vessel occlusion.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in cSDH Maximum thickness From Baseline on Non-contrast Head CT
Délai: Baseline, 1 month (3-6 weeks), and 3 months (10-14 weeks)
|
Change in maximum hematoma thickness (mm) and Volume (mL) measured on non-contrast head CT compared with baseline.
Measurements will be performed using standardized imaging review.
|
Baseline, 1 month (3-6 weeks), and 3 months (10-14 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants Requiring Additional surgical Intervention
Délai: Through 3 months
|
Number of participants requiring additional surgical treatment after randomization, including initial surgical evacuation in the medical management cohort or repeat hematoma evacuation in the surgical cohort.
|
Through 3 months
|
|
Change from Baseline in Modified Rankin scale (mRS) Score
Délai: Baseline, 1 month, and 3 months
|
Functional outcome measured using the Modified Rankin Scale (range 0-6).
change from baseline will be reported.
|
Baseline, 1 month, and 3 months
|
|
Number of participants with Procedure-related Serious Adverse Events
Délai: through 3 months after embolization
|
Number of participants experiencing procedure related adverse events, including but not limited to ischemic stroke, intracranial hemorrhage, arterial dissection, vessel perforation, access-site complications requiring intervention, or death.
|
through 3 months after embolization
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jonathan Pace, MD, Lahey Hospital & Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Blessures et Blessures
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Hémorragie
- Traumatisme crânio-cérébral
- Traumatisme, système nerveux
- Hémorragies intracrâniennes
- Hémorragie intracrânienne, traumatique
- Conditions pathologiques, signes et symptômes
- Hématome sous-dural
- Hématome
- Hématome, sous-dural, chronique
Autres numéros d'identification d'étude
- 20253018
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .